Characterization of mesenchymal stromal cells: potency assay development |
| |
| Authors: | Peiman Hematti |
| |
| Affiliation: | Department of Medicine, University of Wisconsin‐Madison School of Medicine and Public Health, University of Wisconsin Carbone Cancer Center, Madison, Wisconsin |
| |
| Abstract: | Based on their many different mechanisms of action, presumed immune‐privileged status, and relative ease of production, mesenchymal stromal cells (MSCs) are under intensive clinical investigation for treating a wide range of degenerative, inflammatory, and immunologic disorders. Identification of relevant and robust potency assays is not only a regulatory requirement, but it is also the basis for producing and delivering a product that is consistent, safe, and ultimately an effective therapy. Although development of an appropriate potency assay is one of the most challenging issues in cell‐based therapies, it is of paramount importance in the process of developing and testing cellular products. Regardless of the many different tissue sources and methods used in culture expansion of MSCs, they possess many of the same morphologic, cell surface markers, and differentiation characteristics. However, MSC products with similar phenotypic characteristics could still have major differences in their biologic and functional attributes. Understanding the different mechanisms of action and establishment of relevant potency assays is of pivotal importance in allowing investigators and regulatory agencies to compare MSCs used in different clinical trials. |
| |
| Keywords: | |
|
|
